A case of pancreatic cancer after heart transplantation

Teruhiko Imamura; Koichiro Kinugawa; Dai Mohri; Taro Shiga; Miyoko Endo; Toshiro Inaba; Hisataka Maki; Masaru Hatano; Hiroyuki Isayama; Atsushi Yao; Yasunobu Hirata; Kazuhiko Koike; Ryozo Nagai

doi:10.1536/ihj.53.205

A case of pancreatic cancer after heart transplantation

Teruhiko Imamura, Koichiro Kinugawa^*, Dai Mohri, Taro Shiga, Miyoko Endo, Toshiro Inaba, Hisataka Maki, Masaru Hatano, Hiroyuki Isayama, Atsushi Yao, Yasunobu Hirata, Kazuhiko Koike, Ryozo Nagai

^*Corresponding author for this work

Internal Medicine （2）

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Malignancy is not uncommon with immunosuppressive therapy, but pancreatic cancer is infrequently complicated in recipients of heart transplantation. Here we report a transplant case diagnosed with pancreatic cancer 4 years and 8 months after the heart transplantation. We changed the immunosuppressive regimen after the malignancy was detected, and administered everolimus along with chemotherapy using S-1, an oral fluoropyrimidine prodrug. The patient lived for 8 months after the diagnosis, and received metallic stenting for the biliary and duodenal obstruction. Also, to the best of our knowledge, this is the first report about chemotherapy and endoscopic intervention for pancreatic cancer in a heart transplantation patient.

Original language	English
Pages (from-to)	205-207
Number of pages	3
Journal	International Heart Journal
Volume	53
Issue number	3
DOIs	https://doi.org/10.1536/ihj.53.205
State	Published - 2012

Keywords

Everolimus
Heart transplantation
Pancreatic cancer

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1536/ihj.53.205

Cite this

@article{2025ffbee5c74638a237dd2d250dd3aa,

title = "A case of pancreatic cancer after heart transplantation",

abstract = "Malignancy is not uncommon with immunosuppressive therapy, but pancreatic cancer is infrequently complicated in recipients of heart transplantation. Here we report a transplant case diagnosed with pancreatic cancer 4 years and 8 months after the heart transplantation. We changed the immunosuppressive regimen after the malignancy was detected, and administered everolimus along with chemotherapy using S-1, an oral fluoropyrimidine prodrug. The patient lived for 8 months after the diagnosis, and received metallic stenting for the biliary and duodenal obstruction. Also, to the best of our knowledge, this is the first report about chemotherapy and endoscopic intervention for pancreatic cancer in a heart transplantation patient.",

keywords = "Everolimus, Heart transplantation, Pancreatic cancer",

author = "Teruhiko Imamura and Koichiro Kinugawa and Dai Mohri and Taro Shiga and Miyoko Endo and Toshiro Inaba and Hisataka Maki and Masaru Hatano and Hiroyuki Isayama and Atsushi Yao and Yasunobu Hirata and Kazuhiko Koike and Ryozo Nagai",

year = "2012",

doi = "10.1536/ihj.53.205",

language = "英語",

volume = "53",

pages = "205--207",

journal = "International Heart Journal",

issn = "1349-2365",

publisher = "International Heart Journal Association",

number = "3",

}

TY - JOUR

T1 - A case of pancreatic cancer after heart transplantation

AU - Imamura, Teruhiko

AU - Kinugawa, Koichiro

AU - Mohri, Dai

AU - Shiga, Taro

AU - Endo, Miyoko

AU - Inaba, Toshiro

AU - Maki, Hisataka

AU - Hatano, Masaru

AU - Isayama, Hiroyuki

AU - Yao, Atsushi

AU - Hirata, Yasunobu

AU - Koike, Kazuhiko

AU - Nagai, Ryozo

PY - 2012

Y1 - 2012

N2 - Malignancy is not uncommon with immunosuppressive therapy, but pancreatic cancer is infrequently complicated in recipients of heart transplantation. Here we report a transplant case diagnosed with pancreatic cancer 4 years and 8 months after the heart transplantation. We changed the immunosuppressive regimen after the malignancy was detected, and administered everolimus along with chemotherapy using S-1, an oral fluoropyrimidine prodrug. The patient lived for 8 months after the diagnosis, and received metallic stenting for the biliary and duodenal obstruction. Also, to the best of our knowledge, this is the first report about chemotherapy and endoscopic intervention for pancreatic cancer in a heart transplantation patient.

AB - Malignancy is not uncommon with immunosuppressive therapy, but pancreatic cancer is infrequently complicated in recipients of heart transplantation. Here we report a transplant case diagnosed with pancreatic cancer 4 years and 8 months after the heart transplantation. We changed the immunosuppressive regimen after the malignancy was detected, and administered everolimus along with chemotherapy using S-1, an oral fluoropyrimidine prodrug. The patient lived for 8 months after the diagnosis, and received metallic stenting for the biliary and duodenal obstruction. Also, to the best of our knowledge, this is the first report about chemotherapy and endoscopic intervention for pancreatic cancer in a heart transplantation patient.

KW - Everolimus

KW - Heart transplantation

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84863455405&partnerID=8YFLogxK

U2 - 10.1536/ihj.53.205

DO - 10.1536/ihj.53.205

M3 - 学術論文

C2 - 22790692

AN - SCOPUS:84863455405

SN - 1349-2365

VL - 53

SP - 205

EP - 207

JO - International Heart Journal

JF - International Heart Journal

IS - 3

ER -

A case of pancreatic cancer after heart transplantation

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this